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Obesity is closely linked to a wide array of pathophysio-logical conditions, including insulin resistance.1 The adi-
pose tissue is an important endocrine organ that produces and 
secretes biologically active molecules, collectively known as 
adipokines.2 Obesity is accompanied by a chronic, low-grade 
inflammation, characterized by a dysregulated production of 
proinflammatory adipokines, such as tumor necrosis factor-α, 
interleukin-6, and plasminogen activator inhibitor-1(PAI-1), 
and anti-inflammatory adipokines, such as adiponectin.3–5 It 
has been proposed that this dysregulation is a key feature in the 
pathogenesis of obesity-related insulin resistance.6–8 However, 
mechanisms by which excessive fat accumulation leads to a 
dysregulation of adipokines have not yet been elucidated.
The receptor for advanced glycation end products (RAGE) is 
a pattern-recognition receptor and is a multiligand  cell-surface 
molecule expressed on different cell types, such as adipocytes, 
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Objective—Dysregulation of inflammatory adipokines by the adipose tissue plays an important role in obesity-associated 
insulin resistance. Pathways leading to this dysregulation remain largely unknown. We hypothesized that the receptor 
for advanced glycation end products (RAGE) and the ligand Nε-(carboxymethyl)lysine (CML) are increased in adipose 
tissue and, moreover, that activation of the CML–RAGE axis plays an important role in obesity-associated inflammation 
and insulin resistance.
Approach and Results—In this study, we observed a strong CML accumulation and increased expression of RAGE in adipose 
tissue in obesity. We confirmed in cultured human preadipocytes that adipogenesis is associated with increased levels of 
CML and RAGE. Moreover, CML induced a dysregulation of inflammatory adipokines in adipocytes via a RAGE-dependent 
pathway. To test the role of RAGE in obesity-associated inflammation further, we constructed an obese mouse model that 
is deficient for RAGE (ie, RAGE–/–/LeptrDb–/– mice). RAGE–/–/LeptrDb–/– mice displayed an improved inflammatory profile 
and glucose homeostasis when compared with RAGE+/+/LeptrDb–/– mice. In addition, CML was trapped in adipose tissue in 
RAGE+/+/LeptrDb–/– mice but not in RAGE–/–/LeptrDb–/–. RAGE-mediated trapping in adipose tissue provides a mechanism 
underlying CML accumulation in adipose tissue and explaining decreased CML plasma levels in obese subjects. Decreased 
CML plasma levels in obese individuals were strongly associated with insulin resistance.
Conclusions—RAGE-mediated CML accumulation in adipose tissue and the activation of the CML–RAGE axis are 
important mechanisms involved in the dysregulation of adipokines in obesity, thereby contributing to the development of 
obesity-associated insulin resistance.  (Arterioscler Thromb Vasc Biol. 2014;34:1199-1208.)
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endothelial cells, and macrophages.9 RAGE is initially identified 
as the receptor for advanced glycation end products (AGEs),10 
but, in addition to AGEs, RAGE also interacts with multiple 
members of the proinflammatory S100/calgranulin family and 
high motility group box 1 protein.9,11 Binding of these ligands 
to RAGE leads to activation of signaling cascade and induction 
of nuclear factor-κB, which can subsequently lead to the pro-
duction of inflammatory mediators.9,12 Therefore, the potential 
role of RAGE in the regulation of inflammation suggests that 
RAGE might be an important mechanism contributing to obe-
sity-associated dysregulation of adipokines and development of 
insulin resistance. Nε-(carboxymethyl)lysine (CML) is a major 
AGE and is an important ligand for RAGE.10 CML is formed on 
proteins by nonenzymatic glycation and oxidation reactions.13 
Alternative routes for CML formation have been described, 
including lipid peroxidation of polyunsaturated fatty acids.14,15 In 
fact, lipid peroxidation is a more important source for CML for-
mation than glycoxidation reactions.14 Because of the reaction 
mechanism, CML formation is increased under hyperglycemic 
and hyperlipidemic conditions. The adipose tissue in obese con-
ditions is characterized by increased levels of fatty acids, lipid 
peroxidation, and oxidative stress. Therefore, we can deduce that 
obesity is also a condition in which CML formation is increased 
and where CML can interact with RAGE. However, the role of 
CML-RAGE in obesity,  obesity-associated inflammation, and 
insulin resistance has to date not been investigated.
The aim of this study was to investigate the role of CML–
RAGE axis in obesity-associated inflammation and insulin 
resistance. In the present study, we showed in humans, in an in 
vitro model of human adipocytes, and in mice lacking RAGE 
on a LeptrDb–/– background, the importance of the CML–RAGE 
axis in the development of obesity-related inflammation and 
insulin resistance.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
CML Accumulation and RAGE Expression 
Are Increased in Human Adipose Tissue
To evaluate whether CML accumulates in human adipose tis-
sue, we performed immunohistochemistry on biopsies of sub-
cutaneous adipose tissue (SAT) of lean and obese subjects. 
Main characteristics of the lean (n=9) and obese subjects 
(n=10) are presented in the Table. Immunohistochemical stain-
ing for CML showed that CML was only slightly detectable in 
SAT of lean subjects, whereas CML was abundantly present in 
SAT of obese subjects (Figure 1A). Semiquantitative analysis 
of the CML staining demonstrated a significantly higher CML 
intensity in SAT of obese subjects when compared with that of 
lean subjects (Figure 1B). RAGE expression was also slightly 
higher in obese SAT versus lean SAT although not significant 
(P=0.189; Figure 1C). However, Western blot analysis dem-
onstrated that RAGE protein levels were significantly higher 
in SAT of obese subjects versus lean controls (Figure 1D).
To analyze CML localization in adipose tissue and to study 
CML accumulation in different fat depots further, we also con-
ducted immunohistochemical stainings of SAT and visceral 
adipose tissue (VAT) obtained from severely obese subjects 
(n=44; body mass index, >40 kg/m2). Main characteristics of the 
severely obese subjects are presented in Table I in the online-only 
Data Supplement. We demonstrated that CML-modified proteins 
were particularly evident in adipocytes, CD68-positive macro-
phages, and CD31-positive endothelial cells (Figure 1E). In addi-
tion, RAGE showed a similar localization as CML (Figure 1E). 
No differences in CML and RAGE localization were observed 
between SAT and VAT. However, a significant higher CML accu-
mulation (Figure 1F) was detected in VAT when compared with 
SAT of severely obese subjects. In addition, RAGE gene expres-
sion levels and RAGE protein levels detected by Western blotting 
(Figure 1G and 1H) were significantly higher in VAT when com-
pared with SAT of severely obese subjects.
These data demonstrate that obesity is associated with an 
accumulation of CML and an increased RAGE gene expres-
sion and RAGE protein levels in adipose tissue, with higher 
CML accumulation and RAGE in VAT than in SAT.
CML Levels Are Increased During Adipocyte 
Lipid Accumulation and Induce Inflammation
To investigate the role of the CML–RAGE axis in adipose 
tissue, we performed an in vitro experiment with human 
Simpson–Golabi–Behmel syndrome (SGBS) preadipocytes 
and differentiated SGBS adipocytes as a model for adipogen-
esis. SGBS preadipocytes were differentiated to mature SGBS 
adipocytes, which resulted in marked lipid accumulation as 
detected by Oil Red O staining (Figure 2A). During the course 
of differentiation, CML levels were significantly increased. 
In addition, RAGE gene expression and protein levels also 
showed a significant increase during differentiation of preadi-
pocytes to adipocytes (Figure 2A).
Nonstandard Abbreviations and Acronyms
AGEs advanced glycation end products
CML Nε-(carboxymethyl)lysine
PAI plasminogen activator inhibitor
RAGE receptor for AGEs
SAT subcutaneous adipose tissue
SGBS Simpson–Golabi–Behmel syndrome
VAT visceral adipose tissue
Table.  General Characteristics of Lean and Obese Subjects
Lean Subjects Obese Subjects
n 9 10
Age, y 59.2±7.4 59.6±9.9
Sex (men), % 100 100
BMI, kg/m2 23.4±1.1 34.2±4.0*
Fasting glucose, mmol/L 5.3±0.3 5.9±0.5†
Fasting insulin, mmol/L 12.2±2.7 22.0±6.8†
GIR, μmol×kg body 
weight–1×min–1
37.1±7.9 14.3±7.9*
Data are presented as mean±SD, or as percentage. BMI indicates body mass 
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We next investigated whether the increase of the CML–RAGE 
axis during adipogenesis is associated with an altered inflamma-
tory profile in preadipocytes and adipocytes. The effect of CML 
on adipocyte inflammation was examined by incubating SGBS 
preadipocytes and adipocytes with different modifications of 
CML-albumin (ie, control-albumin and minimally and highly 
modified CML-albumin).16 Increasing grades of CML modifica-
tion of albumin were determined by UPLC-Tandem MS (ultra 
performance liquid chromatography-tandem mass spectrom-
etry) and Western blotting (data not demonstrated). Long-term 
incubation of SGBS preadipocytes with different CML-albumin 
(for 72 hours) demonstrated a significant increase of RAGE, 
interleukin-6, and PAI-1 gene expression, whereas adiponectin 
expression significantly decreased. Incubation of SGBS preadi-
pocytes during short incubation periods had no effect on RAGE, 
interleukin-6, PAI-1, and adiponectin gene expression (Figure 
I in the online-only Data Supplement). Interestingly, in SGBS 
adipocytes, CML increased the RAGE, interleukin-6, and PAI-1 
gene expression after a short stimulation with CML, whereas 
adiponectin expression decreased (Figure 2B). In both SGBS 
preadipocytes and adipocytes, highly modified CML-albumin 
had a greater effect on expression levels of inflammatory mark-
ers than minimally modified CML-albumin, demonstrating a 
dose-dependent effect of CML.
Figure 1. Nε-(Carboxymethyl)lysine (CML) and receptor for advanced glycation end product (RAGE) in human adipose tissue in obesity.  
A, CML immunostaining of subcutaneous adipose tissue (SAT) of lean and obese subjects demonstrated that CML was only slightly 
detectable in SAT of lean subjects, whereas CML was abundantly present in SAT of obese subjects. B, Quantification of the CML immu-
nostaining in SAT demonstrated a significant higher CML staining in obese when compared with that in lean subjects. C, RAGE expres-
sion was slightly higher in SAT of obese subjects when compared with that of lean subjects (P=0.189). RAGE expression levels of the 
obese subjects are presented relative to those of the lean subjects. D, Representative Western blot analyses of RAGE and β-actin protein 
bands of 3 lean and 3 obese subjects are given. Quantification of the RAGE protein levels demonstrated that RAGE protein levels were 
significantly higher in SAT of obese subjects when compared with that of lean subjects. RAGE protein levels were normalized for β-actin 
levels. E, Immunostainings of CML, CD68, CD31, and RAGE in visceral adipose tissue (VAT) of severely obese subjects demonstrated 
that CML and RAGE were detected in adipocytes (arrow 1), macrophages (arrow 2), and endothelial cells (arrow 3). F, Quantification of 
the CML staining demonstrated that CML staining of adipocytes of VAT was significantly higher than CML staining of SAT. G, RAGE 
expression was significantly higher in VAT when compared with SAT of severely obese subjects. RAGE expression levels in the VAT of 
the severely obese subjects are presented relative to those in the SAT. H, Representative RAGE and β-actin Western blot analyses of SAT 
and VAT from 1 severely obese subject are given. Quantification demonstrated that RAGE protein levels were significantly higher in VAT 
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To confirm the role of RAGE in the CML-mediated expres-
sion of inflammatory markers, preadipocytes and adipocytes 
were preincubated with anti-RAGE antibody or soluble 
RAGE (sRAGE). Inhibition of RAGE by anti-RAGE anti-
body and sRAGE led to the normalization of CML-induced 
RAGE, PAI-1, interleukin-6, and adiponectin gene expression 
in SGBS adipocytes (Figure 2C) and preadipocytes (Figure II 
in the online-only Data Supplement).
Also, the incubation of SGBS preadipocytes and adipo-
cytes with S100 protein, which is another important ligand for 
RAGE,17 showed upregulation of RAGE, PAI-1, and interleu-
kin-6 genes and downregulation of adiponectin gene expression 
(Figure 2D; Figure III in the online-only Data Supplement).
These experiments, therefore, demonstrate in an in vitro 
model of excessive lipid accumulation that adipogenesis is 
associated with increased levels of CML-modified proteins, 
increased RAGE expression, and activation of the CML–
RAGE axis leading to changes in expression of adipokines, 
thus indicating that RAGE plays a central role in dysregula-
tion of adipokines associated with obesity.
Obese, RAGE-Deficient Mice Are Associated 
With Improved Inflammation, Improved Insulin 
Resistance, and Increased Plasma CML Levels
To define the role of RAGE in inflammation in obesity in 
vivo further, we developed obese, RAGE-deficient (RAGE–/–/
LeptrDb–/–) and obese, wild-type (RAGE+/+/LeptrDb–/–) mice. In 
the LeptrDb background, no effect of RAGE on body weight was 
observed (39±5 and 35±5 g, respectively) at 9 weeks. RAGE–/–/
LeptrDb–/– mice exhibited an improved inflammatory profile when 
compared with RAGE+/+/LeptrDb–/– mice. RAGE deficiency was 
associated with significant decreased levels of proinflammatory 
cytokines interleukin-1β,  interleukin-12p70, interferon-γ, and 
tumor necrosis factor-α (P<0.05). Proinflammatory cytokine, 
interleukin-6 and mKC (mouse keratinocyte-derived chemo-
kine [the mouse analoge of human interleukin-8]), levels were 
also lower in RAGE–/–/LeptrDb–/– mice but were not statistically 
significant (P=0.131 and 0.200, respectively). The anti-inflam-
matory cytokines,  interleukin-10 and adiponectin (P=0.337 
and 0.103), tend to be higher in RAGE–/–/LeptrDb–/– mice when 
compared with those in RAGE+/+/LeptrDb–/– mice (Figure 3A). 
In addition, we also calculated an overall inflammation score of 
all individual inflammatory markers (interleukin-1β, interleu-
kin-12p70, interferon-γ, tumor necrosis factor-α, interleukin-6, 
mKC (interleukin-8), adiponectin, and interleukin-10) by aver-
aging the z scores of each of the respective markers (z score 
of an inflammatory marker=[individual’s observed value–
mean]/SD). This combined overall inflammation score was sig-
nificantly lower in the RAGE–/–/LeptrDb–/– mice when compared 
with that in RAGE+/+/LeptrDb–/– mice (–0.6±0.2 versus 0.7±0.2; 
P<0.01). Moreover, RAGE deficiency in obese mice led to nor-
malization of the inflammatory markers because the levels of 
inflammatory markers were comparable with those of RAGE+/+/
LeptrDb+/+ mice (Figure 3A). The same pattern of inflamma-
tory cytokines emerged in RAGE deficiency mice when com-
pared with wild-type mice (Figure IV in the  online-only Data 
Supplement).
In addition, RAGE–/–/LeptrDb–/– mice were also associated 
with altered metabolic phenotype. Glucose tolerance test 
demonstrated significant differences in response to glucose 
load between RAGE–/–/LeptrDb–/– and RAGE+/+/LeptrDb–/– mice 
(Figure 3B). RAGE–/–/LeptrDb–/– mice had an improved glucose 
metabolism when compared with RAGE+/+/LeptrDb–/– mice 
(Figure 3B). After insulin injection, glucose did not signifi-
cantly decrease in RAGE+/+/LeptrDb–/– mice (from 24.09±1.32 
mmol/L at time 0 minutes to 28.38±0.99 mmol/L at time 120 
minutes). In contrast, insulin injection declined blood glucose 
by 30% in RAGE–/–/LeptrDb–/– mice (from 26.40±2.31 mmol/L 
at time 0 minutes to 18.81±2.64 mmol/L at time 90 minutes; 
Figure 3C). These results, therefore, demonstrate that RAGE 
deficiency is associated with a general increase in glucose tol-
erance and insulin sensitivity.
Circulating CML Is Trapped in Adipose 
Tissue of RAGE/LeptrDb Mice
Of interest, CML plasma levels were significantly higher in 
RAGE–/–/LeptrDb–/– mice when compared with RAGE+/+/LeptrDb–/– 
mice (923±114 nmol/L versus 684±78nM, P<0.050), and in 
RAGE–/– mice compared with wild-type mice (Figure IV in the 
online-only Data Supplement), indicating that RAGE also rep-
resents a mechanism for the regulation of CML plasma levels.
A possible mechanism whereby RAGE regulates plasma CML 
levels is a selective uptake of circulating CML in specific tissues 
or organs. We first investigated the uptake of circulating CML in 
obesity using LeptrDb–/– mice. We injected LeptrDb–/– mice with 
fluorescently labeled CML-albumin (green fluorescent signal) 
and visualized the distribution and accumulation of the injected 
CML-albumin. As a control, we used a fluorescently labeled con-
trol-albumin (red fluorescent signal), which was simultaneously 
injected with  CML-albumin in LeptrDb–/– mice. After injection, 
plasma clearance of fluorescently labeled CML-albumin was sig-
nificantly faster than that of control-albumin (t
1/2
=59±5 minutes 
Figure 2. Nε-(Carboxymethyl)lysine (CML)–receptor for advanced glycation end product (RAGE) axis is increased during adipogenesis, 
and activation of this pathway mediates adipokine dysregulation in human adipocytes. A, Differentiation of Simpson–Golabi–Behmel 
syndrome (SGBS) preadipocytes to adipocytes was evaluated by an Oil Red O staining and showed a significant lipid accumulation dur-
ing adipogenesis. CML levels (determined by UPLC-Tandem MS [ultra performance liquid chromatography-tandem mass spectrometry]), 
RAGE gene expression (determined by quantitative RT-PCR [real-time polymerase chain reaction]), and RAGE protein levels (determined 
by Western blotting) were significantly increased during the differentiation process. #P<0.05, *P<0.01 vs day 0. B, Incubation of SGBS 
adipocytes with minimally (dotted line) and highly modified CML-albumin (black line) increased the expression of RAGE and downstream 
genes plasminogen activator inhibitor (PAI)-1 and interleukin (IL)-6, and decreased adiponectin expression in a time- and concentration-
dependent manner. Minimally and highly modified CML-albumin were prepared and characterized as described before.16 The expres-
sion levels of each gene are presented relative to those of the control-albumin–treated cells for each time point. #P<0.05 minimally 
modified CML vs control-albumin, †P<0.05 and *P<0.01 highly modified CML-albumin vs control-albumin. C, Preincubation of SGBS 
adipocytes with anti-RAGE antibody or soluble RAGE (sRAGE) inhibited the CML-increased expression of RAGE, PAI-1, and IL-6 and the 
CML-decreased expression of adiponectin. #P<0.05 and *P<0.01 CML-albumin vs control-albumin, ##P<0.05 and **P<0.01 anti-RAGE 
antibody/sRAGE vs CML-albumin. D, Incubation with S100 protein increased the RAGE, PAI-1, and IL-6 gene expression in SGBS adipo-
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versus 139±13 minutes; Figure 4A). CML-albumin and control-
albumin were distributed via the circulation and were visualized in 
the liver and kidney (Figure 4B). Importantly, both CML-albumin 
and control-albumin were colocalized and were restricted to the 
circulation of these tissues. However, a strong accumulation of 
CML-albumin was observed in adipose tissue of LeptrDb–/– mice, 
whereas control-albumin was not detectable in the adipose tissue 
(Figure 4B). These experiments, therefore, showed that adipose 
tissue itself is able to trap CML from the circulation actively and 
selectively, thereby contributing to local CML accumulation in 
adipose tissue in obesity and decreased plasma CML levels.
To study the localization of the injected CML-albumin in adi-
pose tissue in detail, we injected only green fluorescently labeled 
CML-albumin in LeptrDb–/– mice and stained the adipose tissue 
after isolation for CD31 to visualize the endothelial cells (red fluo-
rescently labeled anti-CD31 antibody). Adipocytes showed blue 
autofluorescence. Fluorescently labeled CML-albumin was pres-
ent at the site of administration, namely the vasculature of the adi-
pose tissue, but more importantly, CML-albumin was also detected 
in the cytosol and at the membrane of adipocytes (Figure 4C).
To investigate the role of RAGE in the trapping of CML, 
we repeated this CML trapping experiment in our unique 
mice model (ie, RAGE–/–/LeptrDb–/– and RAGE+/+/LeptrDb–/– 
mice). RAGE–/–/LeptrDb–/– and RAGE+/+/LeptrDb–/– mice were 
injected with fluorescently labeled CML-albumin (red fluo-
rescently signal). A significant accumulation of CML-albumin 
was observed in adipose tissue of RAGE+/+/LeptrDb–/– mice, 
whereas the fluorescently labeled CML-albumin was com-
pletely absent in adipose tissue of RAGE–/–/LeptrDb–/– mice 
(Figure 4D). This indicates that circulating CML is trapped in 
the adipose tissue via a RAGE-dependent mechanism. From 
that observation, we can deduce that RAGE-mediated trap-
ping of CML in adipose tissue contributes to the local accu-
mulation of CML in adipose tissue in RAGE+/+/LeptrDb–/– mice, 
which is associated with a decrease of plasma CML levels.
CML Plasma Levels Are Decreased 
in Obesity in Humans
To investigate whether obesity is associated with decreased 
plasma CML in humans, CML plasma levels were measured in 
Figure 3. Improved regulation of adipokines and glucose homeostasis in obese, RAGE-deficient mice. A, Circulating levels of proinflam-
matory markers—interleukin (IL)-1β, IL-12p70, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, IL-6, and mKC (IL-8)—and anti-inflam-
matory cytokines—adiponectin and IL-10—were measured in RAGE+/+/LeptrDb+/+ mice (shaded bars), RAGE+/+/LeptrDb–/– mice (white bars), 
and RAGE–/–/LeptrDb–/– mice (black bars) and compared between groups. B, After injection of glucose, glucose levels were lower at all time 
points in RAGE–/–/LeptrDb–/– (● , dotted line) vs RAGE+/+/LeptrDb–/– (○, black line) mice. #Overall P<0.01. C, After injection of insulin, maximum 
glucose decline was 30% in RAGE–/–/LeptrDb–/– (● , dotted line) mice, whereas glucose concentrations did not change in the RAGE+/+/Lep-
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lean and obese subjects. As demonstrated in Figure 5A, plasma 
protein–bound CML concentrations were significantly lower in 
obese when compared with those in lean subjects. Additional 
analyses demonstrated strong inverse correlations between 
protein-bound CML plasma concentrations and body mass 
index (Figure 5B). These data indicate that the CML accumula-
tion observed in obese adipose tissue is accompanied by lower 
circulating protein–bound CML levels, suggesting that a CML 
trapping mechanism is operating in humans. This decrease of 
plasma protein–bound CML levels in obesity and the correla-
tion with body mass index were confirmed in severely obese 
subjects (Figure V in the online-only Data Supplement).
We also evaluated the effect of weight loss on plasma 
CML levels. Plasma samples from severely obese subjects 
undergoing bariatric surgery were taken before and 6 months 
after surgery. During this period, they lost 16±9 kg on aver-
age. Their mean body mass index was 41.7±3.1 kg/m2 before 
surgery and 36.3±4.4 kg/m2 after 6 months. As demonstrated 
in Figure 5C, weight loss by bariatric surgery was associated 
with an increase of CML plasma levels.
CML Plasma Levels Are Associated 
With Insulin Resistance in Humans
The association of decreased plasma levels of CML 
in obesity with insulin resistance, as determined by a 
 hyperinsulinemic-euglycemic clamp, was investigated in 
obese subjects (n=10) and lean controls (n=9). Obese subjects 
had a significantly lower insulin sensitivity when compared 
with lean subjects (glucose infusion rate, 16.1±9.6 versus 
37.4±8.3 μmol×kg body weight–1×minutes–1; P<0.001). A 
strong correlation was found between CML plasma concen-
trations and insulin sensitivity (r=0.669; P<0.01; Figure 5D), 
indicating that low CML plasma levels in obesity are associ-
ated with high insulin resistance.
Discussion
Here we show, for the first time, a role of the CML–RAGE axis in 
obesity-associated dysregulation of adipokines and in the develop-
ment of obesity-related insulin resistance. First, we demonstrated 
in humans and in an in vitro model of adipogenesis that obesity is 
associated with increased CML accumulation and RAGE expres-
sion. Second, we found that the activation of this CML–RAGE 
axis resulted in a dysregulated expression of pro- and anti-inflam-
matory cytokines. We found that the RAGE–/–/LeptrDb–/– mice were 
characterized by improved inflammatory profile and improved 
insulin sensitivity. Third, we also found a RAGE-mediated trap-
ping of CML in adipose tissue in RAGE–/–/LeptrDb–/– mice. In line 
with this concept, we also found decreased CML plasma level in 
obese subjects, and this decrease in CML was associated with 
decreased insulin sensitivity in obese subjects. Taken together, 
this study demonstrates a novel function of RAGE in regulating 
CML levels in obesity, and that the activation of the CML–RAGE 
axis plays a major role in the dysregulation of adipokines and the 
development of obesity-associated insulin resistance.
Although CML has been regarded as a traditional AGE 
formed from glucose, increasing numbers of reports have 
emphasized that CML is mainly formed from lipid peroxida-
tion reactions and can, therefore, be considered as an advanced 
lipoxidation end product.14,18 The increased oxidation of fatty 
Figure 4. Trapping of Nε-(carboxymethyl)lysine (CML) in adi-
pose tissue is mediated by receptor for advanced glycation end 
product (RAGE). A, Clearance of CML-albumin from circulation 
was significantly faster than the clearance from control-albumin. 
*P<0.001. B, Trapping of CML-albumin (green fluorescent signal) 
and  control-albumin (red fluorescent signal) in adipose tissue, 
liver, and kidney was studied in LeptrDb–/– mice using 2-photon 
microscopy. This demonstrated that only CML-albumin could 
be detected in adipose tissue, whereas in liver and kidney both 
CML-albumin and control-albumin were present. C, (i) High vas-
cularization of the adipose tissue (adipocytes showed blue auto-
fluorescence) was observed after staining the adipose tissue with 
an antibody against endothelial marker CD31 (red fluorescence); 
(ii and iii) overlay images showed that CML-albumin (green 
fluorescent signal) is found at site of administration (ie, in the 
circulation), but more importantly CML-albumin was found in the 
cytoplasm and at the membrane of adipocytes (see arrows). D, 
Fluorescently labeled CML-albumin (red fluorescent signal) was 
detected in adipocytes of RAGE+/+/LeptrDb–/– mice, whereas no 
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acids and formation of lipid peroxidation products in obese 
conditions prompted us to hypothesize that CML formation 
is increased in obesity. Our in vitro data confirmed that lipid 
accumulation during differentiation of adipocytes was associ-
ated with increased endogenous CML formation. In addition, 
we demonstrated in human adipose tissue that CML accumula-
tion is higher in adipose tissue of obese subjects when com-
pared with that in adipose tissue of lean subjects. In VAT, we 
found more CML accumulation than in SAT of obese subjects. 
This study is the first study investigating CML accumulation 
in human adipose tissue. Other studies have already demon-
strated in other tissues that the obese state is associated with 
local CML accumulation. Our previous study demonstrated that 
development of fatty livers was associated with increased for-
mation of CML in lipid-laden hepatocytes.19 In addition, CML 
accumulation was observed in the muscle tissue of obese sub-
jects, which was correlated with weight gain.20 These data and 
our study reveal that obesity increases levels of CML, probably 
through increased lipid peroxidation. However, we cannot fully 
rule out potential roles of other pathways in the formation of 
CML. Previous work by others suggested potential roles for the 
myeloperoxidase family of enzymes in generation of CML.21
CML exerts biological effects via altered gene expression 
mediated by RAGE.9 CML-activation of RAGE triggers multiple 
signaling cascades, resulting in activation and translocation of 
nuclear transcription factors (nuclear factor-κB) and transcrip-
tion of target genes, including inflammatory cytokines.9 It has 
been demonstrated that a positive autoregulatory loop exists on 
RAGE activation by CML, which in turn induces RAGE expres-
sion and subsequent RAGE-mediated perpetuated nuclear factor-
κB activation.12 This indicates that ligation of RAGE results in a 
constantly growing and renewable pool of RAGE, thereby ampli-
fying the inflammatory response. Therefore, we can conceive 
that the CML-rich environment seen in the obese adipose tissue 
may be accompanied by the upregulation of RAGE. In our study, 
we indeed observed that RAGE expression accompanies CML 
accumulation and is also upregulated during differentiation of 
adipocytes. Moreover, RAGE gene expression was higher in adi-
pose tissue of obese subjects when compared with that in adipose 
tissue of lean subjects and was higher in VAT when compared 
with SAT of severely obese subjects. The simultaneous increase 
of CML and RAGE in obesity and the colocalization of RAGE 
and CML in the human adipose tissue support a key role for 
CML–RAGE axis in  obesity-associated inflammation.
Only limited reports have investigated the role of AGEs in 
adipocyte inflammation, and no study to date has investigated 
the role of CML-RAGE in human adipocyte inflammation. 
Unno et al22 already showed that glycolaldehyde-modified 
albumin increased the expression of leptin in mouse adi-
pocytes. Moreover, PAI-1 expression in rat adipocytes was 
upregulated on incubation with nondefined AGEs.23 Our data 
reveal that the incubation of preadipocytes and adipocytes 
with CML increased the expression of inflammatory markers, 
RAGE, PAI-1, and interleukin-6, whereas the expression of 
adiponectin was decreased on CML incubation. In both pre-
adipocytes and adipocytes, we demonstrated that CML has 
functional consequences at the level of adipokine dysregula-
tion. However, in adipocytes, a rapid CML-mediated upregu-
lation of RAGE, PAI-1, interleukin-6, and downregulation of 
adiponectin was observed, whereas a delayed effect of CML 
on expression of inflammatory markers was detected in preadi-
pocytes. Differences in basal RAGE gene expression between 
preadipocytes and adipocytes may underlie this effect. In pre-
adipocytes and adipocytes, we showed that strategies to inhibit 
CML-RAGE interaction or to decoy CML, via administra-
tion of anti-RAGE antibody or soluble RAGE, respectively, 
reduced the CML-mediated inflammatory responses. Our cur-
rent findings are the first to demonstrate a direct role of RAGE 
in human adipocyte inflammation in vitro. In addition, our data 
delineate that CML as ligand for RAGE plays fundamental 
role in RAGE-mediated adipocyte inflammation.
Figure 5. Nε-(Carboxymethyl)lysine (CML) plasma levels are 
decreased in obesity and associated with insulin sensitivity. A, 
CML plasma levels were significantly lower in obese subjects when 
compared with those in lean controls. B, CML plasma levels were 
inversely related with body mass index (BMI). Correlation coef-
ficient is given for this relationship. C, Weight loss by bariatric sur-
gery in severely obese subjects is associated with increased CML 
plasma levels. D, CML plasma levels were associated with glucose 
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We further extended these in vitro observations to in vivo 
ones using a murine model of RAGE deficiency, obesity, and 
type 2 diabetes mellitus, RAGE–/–/LeptrDb–/– mice. Deletion of 
RAGE was protective against inflammation and was associ-
ated with greater insulin sensitivity in insulin tolerance test and 
improved glucose metabolism in glucose tolerance test. RAGE–
/– animals had slightly higher body weights then their littermate 
RAGE+/+ control mice. Because dosing for glucose tolerance 
test and insulin tolerance test was based on total body weight, 
we cannot exclude this difference in body weight and hence 
difference in dosing of glucose and insulin influenced the out-
come of the metabolic tests. However, if anything, this would 
lead to an underestimation of the improved glucose tolerance in 
RAGE–/– mice. Previous research has also demonstrated that 
RAGE deficiency significantly decreased the expression of pro-
inflammatory mediators and lower levels of oxidative stress, 
whereas adiponectin levels and antioxidative defense mecha-
nisms were higher in RAGE-deficient mice.24–28 In addition, the 
favorable effect of RAGE deficiency on insulin sensitivity and 
glucose metabolism was also demonstrated in RAGE knockout 
mice fed a high-fat diet.27,28 RAGE deficiency was also asso-
ciated with higher glucose transporter-4 expression in adipose 
tissue in these mice.28 In cultured adipocytes, nondefined AGEs 
impair insulin signaling by increasing generation of intracel-
lular reactive oxygen species and activation of inflammatory 
pathways.29,30 Ueno et al25 recently demonstrated attenuated 
insulin-stimulated glucose uptake in RAGE-overexpressing 
3T3-L1 adipocytes. Therefore, the RAGE system represents an 
important risk factor for the development of obesity-associated 
inflammation and insulin resistance. Recent reports suggest that 
RAGE itself could be involved in the progression of obesity. In 
ApoE/RAGE double knockout mice, it was demonstrated that 
RAGE regulated adiposity. Monden et al28 demonstrated that an 
increase in body weight induced by high-fat diet is suppressed 
in RAGE knockout mice. In contrast to these studies, we did not 
observe an effect of RAGE on adiposity in the LeptrDb–/– back-
ground. We could speculate that the effect of RAGE on body 
weight does not outweigh the effect of severe obesity caused by 
the genetic mutation in the receptor for leptin. More research 
is needed to clarify these conflicting results and to reveal the 
underlying mechanism.
In the present study, we were intrigued by the finding that 
CML plasma levels were increased in obese,  RAGE-deficient 
mice when compared with RAGE+/+/LeptrDb–/– mice, whereas 
other AGEs, such as Nε-(carboxyethyl)lysine, were not 
affected. This finding, together with the strong colocalization 
of CML and RAGE in human adipocytes and the in vitro CML-
RAGE–mediated adipokine dysregulation, indicates that CML 
is the major ligand for RAGE-mediated inflammation and 
insulin resistances, and that RAGE represents a mechanism 
for regulating CML plasma levels. CML plasma levels were 
unchanged in mice deficient for other AGE receptors, such as 
galectin-3, scavenger receptor A, and CD36 (data not shown), 
indicating that these scavenger receptors do not influence cir-
culating CML levels. We demonstrated that injected fluores-
cently labeled CML was preferentially taken up in adipose 
tissue in mice expressing RAGE when compared with RAGE-
deficient mice. These data, therefore, demonstrated for the first 
time a RAGE-mediated trapping of CML in adipose tissue and 
provided a mechanistic explanation for the improved grade of 
low-grade inflammation and insulin sensitivity observed in the 
obese RAGE-deficient mice.
Because we observed that obesity is associated with CML 
accumulation and increased RAGE expression in human adi-
pose tissue, this might indicate that the increased expression 
of RAGE may lead to increased trapping of CML in adipose 
tissue, thereby contributing to the accumulation of CML in 
adipose tissue and to lower CML plasma levels. In our obese 
population, we indeed demonstrated significantly lower CML 
plasma levels in obese subjects when compared with those 
in lean subjects. Previous studies by Sebeková et al31 dem-
onstrated decreased CML plasma levels in obesity. In obese 
adolescents, lower levels of plasma CML were found when 
compared with their lean counterparts. These authors recently 
confirmed their data in a large cohort of obese and normal 
weight controls (n=437), and, in addition, they demonstrated 
that CML plasma levels showed a decreasing trend with rising 
numbers of risk factors for the metabolic syndrome.32 CML 
plasma levels were also inversely related to fat mass, indicat-
ing that obesity represents a main determinant for the decline 
of CML plasma levels.33 Nevertheless, these epidemiological 
studies do not encounter the underlying mechanism. Our pres-
ent data provide a mechanistic explanation for these findings. 
In our study, we observed increased CML-RAGE accumula-
tion in obese subjects when compared with lean subjects, and 
moreover, CML-RAGE accumulation was higher in VAT when 
compared with SAT of obese subjects. From these observa-
tions, we may deduce that in obese subjects and in VAT, there 
is more RAGE-mediated CML trapping present that explains 
the decrease of circulating CML levels.
Our human study showed, in addition to the CML accumu-
lation in adipocytes, a strong CML staining in macrophages 
of obese adipose tissue. As the adipose tissue is infiltrated 
by inflammatory macrophages during obesity, CML accu-
mulation in these macrophages and macrophage activation 
could also play an important role in adipose tissue inflamma-
tion. It has already been demonstrated that nondefined AGEs 
stimulate the production of tissue factor in cultured human 
monocytes and tumor necrosis factor-α production in rat mac-
rophages. Therefore, the role of RAGE-CML in macrophage 
activation, inflammation, and insulin resistance in obesity 
should be addressed in future studies.
Taken together, our study provides, for the first time, evi-
dence of a novel function of RAGE in trapping of CML in 
adipose tissue in obesity. This RAGE-mediated CML accumu-
lation is an important mechanism involved in the dysregulation 
of adipokines in obesity, thereby contributing to the develop-
ment of obesity-associated insulin resistance. Hence, RAGE-
mediated CML trapping in adipose tissue is a potentially useful 
target for developing new therapies against obesity-associated 
dysregulation of adipokines and its complications.
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